AIM ImmunoTech Competitors and Similar CompaniesClear all

AIM ImmunoTech's competitors and similar companies include ImmuneSensor Therapeutics, CytomX Therapeutics and Carrick Therapeutics.

	AIM ImmunoTech AIM ImmunoTech (formerly known as Hemispherx Biopharma) is an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases.	ImmuneSensor Therapeutics ImmuneSensor Therapeutics is a company aiming to treat cancer and autoimmune diseases.	CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.	Carrick Therapeutics Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments.
Founding Date	Founding Date 1990	Founding Date 2014	Founding Date 2008	Founding Date 2015
Type	Type Public	Type Private	Type Public	Type Private
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Manufacturing & Industrial biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Ocala, US HQ New Brunswick, US	Locations Dallas, US HQ	Locations South San Francisco, US HQ	Locations Dublin, IE HQ Oxford, GB
Employees	Employees 3124% increase	Employees 11	Employees 15815% increase	Employees 17
Valuation ($)	Valuation ($) 17.1 m	Valuation ($) N/A	Valuation ($) 78 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $88k (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $76.2m (FY, 2025)	Revenue (est.) N/A
Net income	Net income ($14m) (FY, 2025)	Net income N/A	Net income ($17.4m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 132.4m	Total funding raised $ 95m